Identifying selective CDK19 inhibitors for Triple-Negative Breast Cancer

在此期间，NCGC一直致力于调整和优化可适应hts的CDK19检测方法，以实现高通量筛选。

During this period, the NCGC has worked to adapt and optimize an HTS-amenable CDK19 assay to enable high-throughput screening. As a center, the NCGC has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.